In current smokers with COPD, LABA plus LAMA is superior to LABA plus ICS, regardless of blood eosinophils. Data from the FLAME trial
Mathioudakis, A. Higham, A. Bate, S. Chatzimavridou-Grigoriadou, Victoria Sivapalan, P. Jensen, J. U. Felton, T. Vestbo, J. Singh, D.
Mathioudakis, A.
Higham, A.
Bate, S.
Chatzimavridou-Grigoriadou, Victoria
Sivapalan, P.
Jensen, J. U.
Felton, T.
Vestbo, J.
Singh, D.
Citations
Altmetric:
Abstract
Description
Date
2024
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Mathioudakis A, Higham A, Bate S, Chatzimavridou-Grigoriadou V, Sivapalan P, Jensen JU, et al. In current smokers with COPD, LABA plus LAMA is superior to LABA plus ICS, regardless of blood eosinophils. Data from the FLAME trial. EUROPEAN RESPIRATORY JOURNAL. 2024 SEP;64. PubMed PMID: WOS:001356665700004. English.